David E. Carpenter

David E. Carpenter

Benzinga Staff Writer

War Vets With Severe PTSD Find Solace Through Ayahuasca In Documentary 'From Shock To Awe'
Here’s a figure that should be seared into the minds of every living American: 22. That’s the shocking number of United States war veterans who commit suicide every single day. Let that number sink in for a minute.
Psychedelic Toads Pushed To The Limit, Conservationists Urge Synthetic 5-MeO-DMT Option
You can add the Sonoran Desert Toad to the current escalating body count of threatened species worldwide, as the amphibious creature’s psychoactive secretions continue to gain popularity with psychedelic enthusiasts.
3 Friends Explore The Obscure And Potent Substance 5-MeO-DMT In This Existentially Intense Film Doc
“Are some doors better left unopened?” That is the ultimate question three friends ask themselves in the captivating documentary film 5MEO. 
As More People Turn To Psychedelics, Integration Proves A Crucial Factor For Breakthroughs
Nick Watchorn had suffered for most of his adult life from severe post-traumatic stress disorder (PTSD) before he sought psychedelic treatments to deal with his chronic condition. He credits those psychoactive sessions, and particularly the work he did afterwards in a process known as integration — a way of gleaning insights from the experience — with saving his life.
From Hunter Biden To HGTV Star Christina Haack, Psychedelic Toad Venom Hits The Mainstream
A once obscure psychoactive substance of the underground, psychedelic toad venom has officially hit the mainstream after HGTV celebrity Christina Haack’s Instagram post about experiencing the potent drug, saying it changed her
Nurses In Psychedelics, Naturals Caring For Patients In Non-Ordinary States Of Consciousness
“It begins with trust,” says Andrew Penn, registered nurse and associate clinical professor at UC San Francisco’s School of Nursing.  Penn is describing how nurses can be naturals at providing care for people in psychedelic states. 
EXCLUSIVE: Psychedelic Treatment Platform Maya Health Raises $4.3M, Bridging Clinical & Real-World Practices' Gap
Psychedelic treatments are on the cusp of being accepted therapies for the masses. Good data will likely help drive best practices.
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.  
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent investors who are backing research into psychedelic ventures.
Psychedelic Therapy Is Poised To Create A Revolution In Mental Health: Can VR Accelerate It?
Legal psychedelic medicine is poised to soon disrupt the multibillion-dollar mental health field.
Novamind Opens Addiction Clinic In Utah, Establishing Substance Use Disorder Program
Novamind Inc. (OTCQB: NVMDF), a mental health company specializing in psychedelic medicine, has announced the launch of a new clinic located in downtown Salt Lake City specializing in integrative behavioral health and services for adults with substance use disorders. 
DEA Supports White House Plan To Streamline Research Of Psychedelics and Cannabis
While testifying at a recent House subcommittee hearing, the Drug Enforcement Administration (DEA) and National Institute On Drug Abuse (NIDA) signaled their willingness to align with a White House proposal that seeks to streamline the process of researching Schedule I drugs.
Psychedelic Medicine: 5-MeO-DMT Formula For Treatment-Resistant Depression Has Positive Trial Results
Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffering from treatment-resistant depression (TRD).
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers
In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “Horizons: Perspectives On Psychedelics” in New York City is an incredible testimony to where the field of psychedelic therapy, and the industry as a whole, is
Federal Foot-Dragging On Cannabis Rescheduling Hampers Vital Research, Harms Veterans And Millions More
The federal government’s current position on cannabis and its stranglehold as a harmful Schedule 1 drug, which makes it ineligible for rigorous medical examination, is hampering vital research on the plant and harming millions of Americans, including veterans.
Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders
Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin Ameri
Marijuana Banking Reform: Millions Among Financial & Labor Groups Seek Banking Services Via Defense Act
In a bid to see marijuana banking reform passed as part of this year’s National Defense Authorization Act (NDAA), vocal members of labor and financial organizations penned a letter to Senate leadership imploring them to afford legitimate cannabis businesses with banking services, which would also give them access to essential insurance products and protec
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of in
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
Cybin (NYSE: CYBN), a biotech company focused on progressing psychedelic therapeutics, has announced that the FDA has given them authorization for Phase 2 clinical trials evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress
New Zealand: First In World To Legalize Drug Checking At Public Events, Frontrunner In Harm Reduction
New Zealand has recently distinguished itself as the first country in the world to legalize drug checking services, most notably for people attending festivals and other events. The decision is a landmark ruling that stresses harm reduction for individuals by testing often illicit substances they plan to consume.